Inflammatix

Burlingame, United States

Inflammatix develops rapid immune system diagnostics to improve patient care and public health.

$57.0M raised

Sep 2024

Series E

Top Investors

Khosla VenturesNational Institutes of HealthOSF VenturesNorthpond VenturesVesalius Biocapital Partners

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Inflammatix raised?

Inflammatix has raised $57.0M in total funding. The most recent round was Series E. The last funding was announced in September 2024.

Who are Inflammatix's investors?

Inflammatix's investors include Khosla Ventures, National Institutes of Health, OSF Ventures, Northpond Ventures, Vesalius Biocapital Partners.

Where is Inflammatix headquartered?

Inflammatix is headquartered in Burlingame, United States.

What does Inflammatix do?

Inflammatix develops rapid immune system diagnostics to improve patient care and public health.

What stage is Inflammatix at?

Inflammatix is at the Series E stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 12, 2024.

MLA

"Inflammatix — Funding & Investors." VCBacked, September 12, 2024, https://www.vcbacked.co/company/inflammatix. Accessed June 4, 2026.

APA

VCBacked. (2024). Inflammatix — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/inflammatix

Wikipedia (cite web)

{{cite web |title=Inflammatix — Funding & Investors |url=https://www.vcbacked.co/company/inflammatix |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 12, 2024.